Pepdexpepdex
Stack
№ 040

IGF-1 DES

A muscle-growth compound that works more on the local muscle than the whole body. A truncated IGF-1 variant (missing the first 3 amino acids) that acts more locally than IGF-1 LR3, with shorter duration and (in theory) less systemic exposure.

GH-axis
Evidence: Anecdotal

IGF-1 DES: A muscle-growth compound that works more on the local muscle than the whole body. A truncated IGF-1 variant (missing the first 3 amino acids) that acts more locally than IGF-1 LR3, with shorter duration and (in theory) less systemic exposure. IGF-1 DES is a shorter version of IGF-1 LR3.

FDA ⓘ
Not approved
WADA
Banned
Typical dose
30-150 mcg sub-q post-workout
Half-life ⓘ
~30 minutes
Route ⓘ
Subcutaneous, often site-specific
Schedule
Daily, post-workout
In plain English

IGF-1 DES is a shorter version of IGF-1 LR3. It works more locally (near the injection site) and clears faster, which (in theory) means less systemic side effect exposure than LR3. Used by lifters for site-specific muscle anabolism.

Status & legalityWhat do these mean? →
Natty? ⓘ
Not natty
FDA ⓘ
Not approved

Not FDA approved. Mecasermin (Increlex) covers IGF-1 generally; DES variant specifically is not approved.

Compounding ⓘ
Not classified

Not on FDA's 503A bulks list and not in any current nomination category, so it does not qualify for compounding from bulk through the bulks-list route. FDA stopped sorting new nominations into those categories in January 2025, so an absent category is not itself a finding either way.

WADA ⓘ
Banned (S2)
Prescribed ⓘ

Not prescribed in conventional medicine.

Who it's for

  • →Users wanting localized muscle anabolism without LR3-level systemic exposure
  • →Site-specific injection users
  • →Short anabolism windows

What to expect

  1. Week 1

    Pumps and fullness in trained muscle.

  2. Week 4

    Site-specific tightness near worked muscle. Cycle endpoint, stop.

  3. Week 8

    Off-cycle. Reassess.

Looking at IGF-1 DES? Your next 3 steps

  1. 1Work out your syringe units

    Vial size + BAC water turns into the exact units to draw for IGF-1 DES.

    Open calculator →
  2. 2See what to stack & monitor

    The companion supplements and the bloodwork worth tracking on this kind of protocol.

    Bloodwork guide →
  3. 3Save it & ask the Coach

    A free account gets you Coach questions every day, free; membership saves your stack and makes the Coach stack-aware.

    Create free account →

How it works (mechanism)

Truncated IGF-1 missing the first 3 amino acids. Binds the IGF-1 receptor with normal affinity but has reduced binding to IGFBPs in some tissues. Shorter duration than LR3, often used for site-specific muscle effects.

Dosing protocol

Members only

Stacks well with

Members only

Side effects

01Hypoglycemia risk (less than LR3 but real)
02Localized growth at injection site
03Headache

When NOT to use

  • ⚠Active malignancy
  • ⚠Diabetic retinopathy
  • ⚠Pregnancy / nursing

Bloodwork to monitor

  • • Fasting glucose every 2 weeks
  • • IGF-1 baseline

Common mistakes

  • • Treating it as IGF-1 LR3 equivalent (different kinetics)
  • • Running longer than 4 weeks
  • • Dosing fasted (hypoglycemia)

What it actually is

IGF-1 DES is a shortened form of insulin-like growth factor 1, missing the first three amino acids. That small deletion has a large consequence: it barely binds the carrier proteins that normally hold IGF-1 inactive, so it is very potent, and it is cleared within about half an hour. The pitch is a strong, brief, local effect rather than the day-long systemic exposure of IGF-1 LR3. There are no human trials of it.

Native IGF-1 spends almost all its time bound to binding proteins, which act as a reservoir and a brake. The missing N-terminal tripeptide is part of what those proteins grip, so DES escapes them. In damaged or exercised tissue, where binding proteins are locally elevated, that difference is amplified — DES stays active where normal IGF-1 would be sequestered. Hence injecting near a trained muscle. Whether that produces localised growth in a person, rather than just a briefly higher systemic IGF-1 level, has never been tested.

Forms, and which is which

Lyophilised powder, subcutaneousHow all use happens

Buyer reconstitutes, often injecting near a trained muscle. Research-chemical supply with unverified identity and potency.

Verdict: The only form, and potency accuracy here is a safety matter.

IGF-1 LR3Systemic, long-acting exposure

The other common analog, with a half-life of about a day rather than half an hour.

Verdict: A different exposure profile, not a stronger version of the same thing.

Recombinant IGF-1 (mecasermin)The approved comparison

Approved for severe primary IGF-1 deficiency in children, with hypoglycaemia warnings and a requirement to dose with food.

Verdict: The regulated version, and its label is the honest guide to the risks.

Blends with growth hormone or insulinNothing

Stacks multiple hypoglycaemia risks. The configuration behind reported serious harms.

Verdict: The most dangerous way to use it.

What it is claimed to do, graded

Produces localised muscle growthNone shown

The reason it is taken and there is no human trial. Zero human trials and zero randomised trial records are indexed.

Is more potent than native IGF-1Moderate

Well established biochemically — the N-terminal deletion reduces binding-protein capture, and a 1989 paper characterised exactly this. Potency is not the same as usefulness.

Has less systemic effect than IGF-1 LR3Limited

Plausible from the short half-life and untested. A shorter-acting compound injected more often is not automatically less systemic.

Is safeNone shown

Hypoglycaemia is the immediate hazard because IGF-1 acts on the insulin receptor. The longer concern is that IGF-1 signalling drives tumour growth, and nothing has excluded that.

Grades describe how much human evidence exists for that specific claim, not whether it will work for you or whether it is safe.

Pros and cons

Pros
  • • Very short half-life, so a dosing mistake resolves quickly
  • • The underlying IGF-1 biology is real and well characterised
  • • An approved recombinant IGF-1 exists, so the risk profile of the pathway is documented
Cons
  • • Zero human trials — grade F on the site's own ladder
  • • Hypoglycaemia is real, immediate and dose-dependent
  • • IGF-1 signalling is implicated in tumour growth, making any undetected cancer a serious concern
  • • Localised action is a theory, not a demonstrated property in people
  • • Banned in sport, and dose accuracy from unregulated supply is a safety issue here

When to stop

  • • Any hypoglycaemic episode: shakiness, sweating, confusion, palpitations — treat it, then stop
  • • Any new lump or unexplained weight loss
  • • Vision changes
  • • Four weeks, on any protocol — nothing supports longer
  • • You cannot reliably have carbohydrate to hand at dosing time

Interactions

InsulinAvoid

Both lower blood glucose and IGF-1 acts on the insulin receptor directly. This combination is behind severe hypoglycaemia events.

Sulfonylureas and other glucose-lowering drugsAvoid

Additive hypoglycaemia with an unpredictable magnitude.

Active or suspected cancerAvoid

IGF-1 is a growth signal for many tumour types. The most serious contraindication here.

Fasted trainingCaution

Dosing without carbohydrate available is the standard route to a hypoglycaemic episode.

Growth hormoneCaution

Growth hormone raises your own IGF-1; adding more compounds both the glucose and growth-signalling concerns.

Is this for you?

Probably worth reading further if
  • • Realistically nobody on the current evidence — and if used at all, only by someone who understands hypoglycaemia management and has glucose to hand
Skip it if
  • • You have active cancer or any undiagnosed lump
  • • You have diabetic retinopathy
  • • You use insulin or are prone to hypoglycaemia
  • • You are pregnant, nursing, or drug-tested in sport
  • • You plan to stack it with growth hormone or insulin

The one number

0 human trials and 0 indexed randomised-trial records; 6 papers total, mostly 1990s biochemistry
Pepdex evidence index — counts are indexed PubMed records, not deduplicated trials; PubMed query for IGF-1 DES

Sources for the claims above

Drug & supplement interactions

  • ⚠Insulin: hypoglycemia risk (less than LR3 but real)
  • ⚠Eat near dose; avoid fasting protocols
Free, no account needed

New to IGF-1 DES? Grab the starter checklist.

Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.

No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.

AI Coach, live sample
Member answer
is 250mcg of bpc enough for a knee injury?
For a knee, is the standard working dose and a solid place to start. The trick with BPC is consistency, give it weeks, not days. , run it , and don't drop below , results tend to fall off under that line. If nothing's moved by week 3, that's when earns its place.
how much bac water for a 10mg reta vial?
is the standard play for a 10 mg reta vial. That gives you , clean unit math across the whole titration: on a 100-unit insulin syringe. Run instead if you want fewer, more concentrated shots. Most people titrate up over , and that mix keeps the numbers cleanest.
what should i track on bloodwork for tirzepatide?
Lipid panel, ALT/AST (liver enzymes), and an A1C, baseline before you start then every 3 months. If you've got metabolic-syndrome history, add fasting glucose and insulin so you can actually watch insulin sensitivity improve. You don't need a big hormone panel for a GLP-1.

Numbers redacted in this preview. Members get the full answer, on their own stack.

Ask the Coach anything about IGF-1 DES or your own stack. This is it working.

Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.

Unlock the full Coach, from $4.99/week →

Frequently asked

What is IGF-1 DES?+
IGF-1 DES is a shorter version of IGF-1 LR3. It works more locally (near the injection site) and clears faster, which (in theory) means less systemic side effect exposure than LR3. Used by lifters for site-specific muscle anabolism.
Is IGF-1 DES FDA approved?+
Not FDA approved. Mecasermin (Increlex) covers IGF-1 generally; DES variant specifically is not approved.
Is IGF-1 DES legal?+
IGF-1 DES is not FDA-approved, so there is no approved prescription version. Most supply is sold as "research only" by peptide vendors. A compounding pharmacy may only use substances the FDA permits for compounding, and many research peptides are not permitted — do not assume a compounded prescription is available. Possession is generally not criminalized but distribution without authorization may be. Verify local laws.
Is IGF-1 DES banned by WADA?+
IGF-1 DES is on the WADA prohibited list under Banned (S2).
Are you still natty after taking IGF-1 DES?+
No. IGF-1 DES is a performance-enhancing peptide and would disqualify a strict natty claim.
Do doctors prescribe IGF-1 DES?+
Not prescribed in conventional medicine.
What's the typical dose of IGF-1 DES?+
Dosing depends on your goal, experience, and tolerance. The full IGF-1 DES protocol (dose, frequency, and how to titrate) is in the members section on the entry page.
What are the side effects of IGF-1 DES?+
Common side effects include: Hypoglycemia risk (less than LR3 but real); Localized growth at injection site; Headache. Less common effects and full safety details are on the entry page.
How long until IGF-1 DES starts working?+
Pumps and fullness in trained muscle.
What can you stack with IGF-1 DES?+
IGF-1 DES is commonly combined with complementary compounds. The full stacking protocol (what to pair, dosing, and timing) is in the members section on the entry page.
Where do people get IGF-1 DES?+
Pepdex does not sell, ship, or recommend suppliers. IGF-1 DES is not FDA-approved; prescription versions require licensed clinical care, and "research only" markets carry real legal and quality risks. /coa explains how to verify a Certificate of Analysis and /guides/scam-vendor-spotting covers the red flags.
IGF-1 DES vs IGF-1 LR3, which is better?+
IGF-1 LR3 vs IGF-1 DES: long-acting systemic vs short-acting local IGF-1 variants. Side effect profiles differ. Full head-to-head comparison: https://pepdex.co/compare/igf-1-lr3-vs-igf-1-des

Common questions about IGF-1 DES

Head-to-head with IGF-1 DES

Compare
IGF-1 DES vs IGF-1 LR3 →

Tracked alongside IGF-1 DES

Same goal, different aisle — each graded on its own evidence in the Pepdex catalog.

MK-677 →
the oral secretagogue these peptides get compared to constantly
Creatine →
the strongest-evidence performance supplement in the catalog
Glycine →
sleep quality drives GH pulses; this is the benign first option
Melatonin →
same reason — the sleep window is the GH window

More in GH-axis

№ 022
HGH (Somatropin)

Recombinant human growth hormone, the protein itself, not a peptide that nudges your body to make more. Highest legal-risk compound in this catalog.

№ 012
MK-677 (Ibutamoren)

Oral ghrelin mimetic. Bumps GH and IGF-1 without injections. Strong appetite stimulation is the trade-off.

№ 007
Ipamorelin

Bumps your natural growth-hormone pulses without hitting cortisol or prolactin. A selective GH secretagogue.

№ 008
CJC-1295 (no DAC)

Pairs with Ipamorelin to amplify your natural growth-hormone pulses. A GHRH analog whose 'no-DAC' version stays short-acting on purpose.